Literature DB >> 16985949

A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy.

William David Henner, Tomasz M Beer.   

Abstract

Although the antineoplastic activity of calcitriol in prostate cancer has been known for many years, the agent's use in oncology has been prevented because of the occurrence of hypercalcemia with daily administration. High-dose pulse administration of calcitriol has the potential to improve the therapeutic index of calcitriol. Results of a phase II study of calcitriol and docetaxel (Taxotere(R)) suggest that this combination may have utility in androgen-independent prostate cancer (AIPC). DN-101, a high-dose (15 mug) formulation of calcitriol suitable for use in oncology, is now being tested in a randomized trial (AIPC Study of Calcitriol Enhancing Taxotere). This formulation of calcitriol could become an important new tool for improving the efficacy of docetaxel in the treatment of AIPC and would join the ranks of other nuclear receptor ligands in cancer treatment. Investigations of DN-101 in the treatment of a broad range of tumor types and in combination with a variety of agents are an exciting new area of research.

Entities:  

Year:  2003        PMID： 16985949      PMCID： PMC1502349     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  15 in total

Review 1.  Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs.

Authors:  G J van den Bemd; H A Pols; J P van Leeuwen
Journal:  Curr Pharm Des       Date:  2000-05       Impact factor: 3.116

Review 2.  Mechanisms for the selective actions of vitamin D analogues.

Authors:  A J Brown
Journal:  Curr Pharm Des       Date:  2000-05       Impact factor: 3.116

3.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

Authors:  C Gross; T Stamey; S Hancock; D Feldman
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

4.  Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.

Authors:  W Berry; S Dakhil; M A Gregurich; L Asmar
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

Review 5.  Non-hypercalcemic pharmacological aspects of vitamin D analogs.

Authors:  R Bouillon; A Verstuyf; L Verlinden; K Allewaert; D Branisteanu; C Mathieu; H van Baelen
Journal:  Biochem Pharmacol       Date:  1995-08-25       Impact factor: 5.858

6.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Authors:  T M Beer; W C Pierce; B A Lowe; W D Henner
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

7.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

8.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.

Authors:  J L Osborn; G G Schwartz; D C Smith; R Bahnson; R Day; D L Trump
Journal:  Urol Oncol       Date:  1995 Sep-Oct       Impact factor: 3.498

9.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.

Authors:  J Picus; M Schultz
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

10.  High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.

Authors:  Tomasz M Beer; Dianne Lemmon; Bruce A Lowe; W David Henner
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860
View more
  3 in total

Review 1.  Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters.

Authors:  Keumhan Noh; Edwin C Y Chow; Holly P Quach; Geny M M Groothuis; Rommel G Tirona; K Sandy Pang
Journal:  AAPS J       Date:  2022-06-01       Impact factor: 3.603

2.  Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Authors:  Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

Review 3.  Vitamins and prostate cancer risk.

Authors:  Krishna Vanaja Donkena; R Jeffrey Karnes; Charles Y F Young
Journal:  Molecules       Date:  2010-03-12       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.